These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 24965573)

  • 1. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers.
    Shi JG; Chen X; Lee F; Emm T; Scherle PA; Lo Y; Punwani N; Williams WV; Yeleswaram S
    J Clin Pharmacol; 2014 Dec; 54(12):1354-61. PubMed ID: 24965573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients.
    Kim H; Brooks KM; Tang CC; Wakim P; Blake M; Brooks SR; Montealegre Sanchez GA; de Jesus AA; Huang Y; Tsai WL; Gadina M; Prakash A; Janes JM; Zhang X; Macias WL; Kumar P; Goldbach-Mansky R
    Clin Pharmacol Ther; 2018 Aug; 104(2):364-373. PubMed ID: 29134648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.
    Papp KA; Menter MA; Raman M; Disch D; Schlichting DE; Gaich C; Macias W; Zhang X; Janes JM
    Br J Dermatol; 2016 Jun; 174(6):1266-76. PubMed ID: 26800231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, Safety, and Tolerability of Single- and Multiple-Dose Once-Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo-Controlled Study.
    Zhao X; Sheng XY; Payne CD; Zhang X; Wang F; Cui YM
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):952-960. PubMed ID: 32945153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers.
    Zhang M; Xu CR; Shamiyeh E; Liu F; Yin JY; von Moltke LL; Smith WB
    J Clin Pharmacol; 2014 Apr; 54(4):415-21. PubMed ID: 24165976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of baricitinib in patients with rheumatoid arthritis.
    Honda S; Harigai M
    Expert Opin Drug Saf; 2020 May; 19(5):545-551. PubMed ID: 32174196
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
    Keystone EC; Taylor PC; Drescher E; Schlichting DE; Beattie SD; Berclaz PY; Lee CH; Fidelus-Gort RK; Luchi ME; Rooney TP; Macias WL; Genovese MC
    Ann Rheum Dis; 2015 Feb; 74(2):333-40. PubMed ID: 25431052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of baricitinib in the treatment of rheumatoid arthritis.
    Richez C; Truchetet ME; Kostine M; Schaeverbeke T; Bannwarth B
    Expert Opin Pharmacother; 2017 Sep; 18(13):1399-1407. PubMed ID: 28737053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baricitinib in Patients with Refractory Rheumatoid Arthritis.
    Genovese MC; Kremer J; Zamani O; Ludivico C; Krogulec M; Xie L; Beattie SD; Koch AE; Cardillo TE; Rooney TP; Macias WL; de Bono S; Schlichting DE; Smolen JS
    N Engl J Med; 2016 Mar; 374(13):1243-52. PubMed ID: 27028914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
    Dougados M; van der Heijde D; Chen YC; Greenwald M; Drescher E; Liu J; Beattie S; Witt S; de la Torre I; Gaich C; Rooney T; Schlichting D; de Bono S; Emery P
    Ann Rheum Dis; 2017 Jan; 76(1):88-95. PubMed ID: 27689735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.
    Guttman-Yassky E; Silverberg JI; Nemoto O; Forman SB; Wilke A; Prescilla R; de la Peña A; Nunes FP; Janes J; Gamalo M; Donley D; Paik J; DeLozier AM; Nickoloff BJ; Simpson EL
    J Am Acad Dermatol; 2019 Apr; 80(4):913-921.e9. PubMed ID: 29410014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials.
    Harigai M; Takeuchi T; Smolen JS; Winthrop KL; Nishikawa A; Rooney TP; Saifan CG; Issa M; Isaka Y; Akashi N; Ishii T; Tanaka Y
    Mod Rheumatol; 2020 Jan; 30(1):36-43. PubMed ID: 30784354
    [No Abstract]   [Full Text] [Related]  

  • 13. Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials.
    Qiu C; Zhao X; She L; Shi Z; Deng Z; Tan L; Tu X; Jiang S; Tang B
    Lipids Health Dis; 2019 Feb; 18(1):54. PubMed ID: 30777075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study.
    Peeva E; Hodge MR; Kieras E; Vazquez ML; Goteti K; Tarabar SG; Alvey CW; Banfield C
    Br J Clin Pharmacol; 2018 Aug; 84(8):1776-1788. PubMed ID: 29672897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.
    Tuttle KR; Brosius FC; Adler SG; Kretzler M; Mehta RL; Tumlin JA; Tanaka Y; Haneda M; Liu J; Silk ME; Cardillo TE; Duffin KL; Haas JV; Macias WL; Nunes FP; Janes JM
    Nephrol Dial Transplant; 2018 Nov; 33(11):1950-1959. PubMed ID: 29481660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis.
    Mogul A; Corsi K; McAuliffe L
    Ann Pharmacother; 2019 Sep; 53(9):947-953. PubMed ID: 30907116
    [No Abstract]   [Full Text] [Related]  

  • 17. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Wallace DJ; Furie RA; Tanaka Y; Kalunian KC; Mosca M; Petri MA; Dörner T; Cardiel MH; Bruce IN; Gomez E; Carmack T; DeLozier AM; Janes JM; Linnik MD; de Bono S; Silk ME; Hoffman RW
    Lancet; 2018 Jul; 392(10143):222-231. PubMed ID: 30043749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis.
    Zhang X; Chua L; Ernest C; Macias W; Rooney T; Tham LS
    CPT Pharmacometrics Syst Pharmacol; 2017 Dec; 6(12):804-813. PubMed ID: 28891251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.
    Banfield C; Scaramozza M; Zhang W; Kieras E; Page KM; Fensome A; Vincent M; Dowty ME; Goteti K; Winkle PJ; Peeva E
    J Clin Pharmacol; 2018 Apr; 58(4):434-447. PubMed ID: 29266308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.
    Veeravalli V; Dash RP; Thomas JA; Babu RJ; Madgula LMV; Srinivas NR
    Drug Saf; 2020 Aug; 43(8):711-725. PubMed ID: 32367507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.